Blood test improves prostate cancer screening
24 August 2021
The Stockholm3 blood test developed by researchers at the Karolinska Institutet in Sweden has been found to improve the prostate cancer screening process.
In a recent study published in The Lancet Oncology, researchers found that Stockholm3 can decrease the number of MRI scans required by around 33%, as well as preventing the identification of minor, low-risk tumours.
This complements the research team’s previous findings, which suggested that magnetic resonance imaging (MRI) could lower overdiagnoses and enhance prostate cancer screening.